Author: Cain, Derek W.; Cidlowski, John A.
Title: After 62 years of regulating immunity, dexamethasone meets COVID-19 Cord-id: etlcyo1j Document date: 2020_8_10
ID: etlcyo1j
Snippet: Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19.
Document: Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and additional co: 1, 2, 3, 4, 5
- adaptive immune system and additional co: 1
Co phrase search for related documents, hyperlinks ordered by date